JAMP-CANDESARTAN TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CANDESARTAN CILEXETIL

Disponible depuis:

JAMP PHARMA CORPORATION

Code ATC:

C09CA06

DCI (Dénomination commune internationale):

CANDESARTAN

Dosage:

16MG

forme pharmaceutique:

TABLET

Composition:

CANDESARTAN CILEXETIL 16MG

Mode d'administration:

ORAL

Unités en paquet:

15G/50G

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Descriptif du produit:

Active ingredient group (AIG) number: 0135220003; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2012-06-06

Résumé des caractéristiques du produit

1
PRODUCT MONOGRAPH
PR
JAMP-CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Angiotensin II
AT
1
Receptor Blocker
JAMP PHARMA CORPORATION
1310
rue
Nobel
Boucherville,
Québec J4B 5H3
Control No. : 229652
Date of Approval:
April 17, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE REACTIONS
..................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND
ADMINISTRATION.........................................................................
18
O V E R D O S A GE
..........................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................... 21
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
.................................................................................25
PHARMACEUTICAL INFORMATION
25
CLINICAL TRIALS
..........................................................................................................
26
DETAILED PHARMACOLOGY
.................................................................................
30
TO X IC OLO G Y
....................................................